newsfilter
← Latest News
Business Wire·

Zura Bio to Participate in the Cantor Global Healthcare Conference

  • Zura Bio Limited management will participate in the Cantor Global Healthcare Conference in New York, NY.
  • A fireside chat is scheduled for Wednesday, September 9, 2026, at 9:10 a.m. ET.
  • One-on-one investor meetings will be conducted on the same day as the fireside chat.
  • The presentation will be live webcast on the company website with a replay available for at least 30 days.
  • Zura is a clinical-stage company developing dual-pathway antibodies for autoimmune and inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is under evaluation in Phase 2 studies TibuSHIELD (hidradenitis suppurativa) and TibuSURE (systemic sclerosis).
  • A third Phase 2 study, NEXUS-PMR for polymyalgia rheumatica, is planned to initiate by year-end 2026.
  • Additional candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies.